Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Mitoxantrone + Pegaspargase in NKTCL
NCT04509466Phase 2Terminated
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Sep 2020
- Primary completion
- Jan 2022
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 2, open-label trial of mitoxantrone hydrochloride liposome in Extranodal NK/T-cell lymphoma nasal type (ENKTCL-NT) (3 arms), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoints: Dose Limiting Toxicities, Complete Response Rate up to 26 weeks and 1 more. Started Sep 2020; status: terminated.
02
Drugs
mitoxantrone hydrochloride liposome
03
Conditions
Extranodal NK/T-cell lymphoma nasal type (ENKTCL-NT)
Beyond the preview
Go deeper on NCT04509466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04509466.